RecruitingNot ApplicableNCT04196842
Heart Failure Precision Medicine Study
Sponsor
University of California, Davis
Enrollment
100 participants
Start Date
Oct 16, 2019
Study Type
INTERVENTIONAL
Conditions
Summary
The study aims to test the hypothesis that multi-omics studies can identify Heart Failure profiles at risk of adverse outcomes and evaluate a telemonitoring intervention in the optimization of guideline-directed medical therapy.
Eligibility
Min Age: 21 Years
Inclusion Criteria3
- Diagnosis of Heart failure
- Objective evidence of cardiac abnormality of structure or function (abnormal ECHO) or elevated levels of B-type natriuretic peptide (\>100 pg/ml)
- HF stage B-D and class I-IV
Exclusion Criteria7
- Patients unable to consent
- Inability to comply with the protocol and follow-up requirements
- Patients unable to use a smartphone
- Patients assessed irregularly (less than two visits in one year)
- History of HTx
- Use of Mechanical circulatory support device (MCSD)
- Comorbidities that, according to the PI, have the potential to interfere with the interpretation of the results
Interventions
DEVICETelemonitoring devices
Set of telemonitoring devices: heart rate and blood pressure monitor, scale and activity tracker.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04196842
Related Trials
Mind Your Heart-II
NCT054311921 location
ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies
NCT071917301 location
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370641 locations
Timing of Coronary Angiography in NSTEMI Complicated by Acute HF
NCT0700216420 locations
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288652 locations